During last week's Barclays Global Healthcare Conference, Pfizer CFO Frank D'Amelio and Senior VP of Investor Relations Chuck Triano told company investors that there could be a "significant opportunity" to increase vaccine prices if the COVID-19 pandemic turns endemic, meaning that the virus is always with the world — not unlike influenza.
D'Amelio and Triano added that people may need a third vaccine to deal with emerging coronavirus variants, or may also require a third dose as a booster.
D'Amelio pointed out that when "normal market conditions" resume, there could be a chance for the company to capitalize on the vaccines from a "demand" and "pricing perspective."
"We believe it's becoming increasingly likely that an annual revaccination is going to take place," he added.
